Hearing loss prevalence and associated factors in chronic kidney disease patients under conservative treatment

Authors

  • Monik Assis Espindula Mota Programa de Pós-Graduação em Saúde Brasileira da Universidade Federal de Juiz de Fora
  • Jose Otávio do Amaral Corrêa Departamento de Ciências Farmacêuticas da Universidade Federal de Juiz de Fora
  • Renato Erothildes Ferreira Programa de Pós-Graduação em Saúde Brasileira da Universidade Federal de Juiz de Fora
  • Matheus Rodrigues Mendes Moraes Faculdade de Medicina da Universidade Federal de Juiz de Fora
  • Bruno Parisi Marlière Faculdade de Medicina da Universidade Federal de Juiz de Fora
  • Fernando Antonio Basile Colugnati Faculdade de Medicina Universidade Federal de Juiz de Fora , Programa de Pós-graduação em Saúde Brasileira da Universidade Federal de Juiz de Fora, Núcleo Interdisciplinar de Estudos e Pesquisas em Nefrologia (NIEPEN), Juiz de Fora, Minas Gerais, Brasil.

DOI:

https://doi.org/10.34019/1982-8047.2020.v46.28887

Keywords:

Chronic Kidney Disease, Hearing Loss, Prevalence, Inflammatory markers, Cytokines

Abstract

Introduction: Hearing loss is an increasingly condition seen in the population. It is found with greater frequency in some specific groups such as elderly people, people with systemic arterial hypertension and diabetes mellitus. Evidence suggests increased prevalence of hearing loss in patients with chronic kidney disease (CKD), however studies in the brazilian population with CKD are scarce. Objective: To evaluate the prevalence of hearing loss in a population of patients with chronic kidney disease non dyalitic and associated factors. Material and methods: We used a convenience sample of patients with CKD (n = 159), aged 18 to 65 years in multidisciplinary healthcare service. The auditory acuity was assessed by pure-tone audiometry threshold and by the questionnaire WHO Ear and Hearing Disorders Survey Protocol for a Population-Based Survey of Prevalence and Causes of Deafness and Hearing Impairment and other Ear Diseases translated and validated into Portuguese. We collected demographic and clinical data, also carried out otoscopy, and dosage of biochemical markers and inflammatory cytokines TNF-α, IFN-γ, IL-1β, IL-6, IL-10, IL-17. Results: In the analyses we checked the prevalence of 25,16% of hearing loss among the participants. In our study we did not find any association between the progression of the stages of CKD and the increase of the prevalence of hearing impairment, nor with its severity. The blood markers analyses, isolated or in association to CKD stages, were not able to establish a relation between the progression of stage of chronic kidney disease and hearing loss. Conclusions: The prevalence of hearing loss in this study is 25,16%. It is recommended that strategies be implemented for the prevention and reversal of this situation in this target group.

Downloads

Download data is not yet available.

References

Seo YJ, Ko SB, Ha TH, Gong TH, Bong JP, Park DJ et al. Association of hearing impairment with chronic kidney disease: a cross sectional study of the Korean general population. BMC Nephrology. 2015; 16:154.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266.

Mansur HN, Colugnati FAB, Grincenkov FRS, Bastos MG. Frailty and quality of life: a cross-sectional study of Brazilian patients with pre-dialysis chronic kidney disease. Health and Quality of Life Outcomes. 2014; 12:27.

Jakic M, Mihaljevi D, Zibar L, Jaki M, Kotromanovi Z, Rogulji: H. Hearing loss in hemodialysis patients. Coll. Antropol. 2010; 34(Suppl. 1):165-71.

Meena RS, Aseri Y, Singh BK, Verma PC. Hearing loss in patients of chronic renal failure: a study of 100 cases. Indian J Otolaryngol Head Neck Surg. 2012; 64(4):356-9.

Abbasi AH, Ramadan R, Hoffman A, Abassi Z. Kidney-Ear Axis. Isr Med Assoc J. 2007; 9(11):814-8.

Thodi C, Thodis E, Danielides V, Pasadakis P, Vargemezis V. Hearing in renal failure. Nephrol Dial Transplant. 2006; 21:3023-30.

Vilayur E, Gopinath B, Harris DC et al. The association between reduced GFR and hearing loss: a cross-sectional population-based study. Is J Kidney Dis. 2010; 56:661-9.

World Health Organization. Global estimates on prevalence of hearing loss: 2018. [Citado em 2018 Out 20]. Disponível em: http://www.who.int/pbd/deafness/estimates/en/.

World Health Organization. WHO Ear and Hearing Disorders Survey: protocol for a population-based survey of prevalence and causes of deafness and hearing impairment and other ear diseases. Prevention of Blindness and Deafness (PBD). Geneva: WHO; 1999.

Béria JB, Raymann BCW, Gigante LP, Figueiredo ACL et al. Hearing impairment and socioeconomic factors: a population-based survey of an urban locality in southern Brazil. Pan Am J Public Health. 2007; 21(6):381-7.

World Health Organization. Hearing impairment grades. [Citado em 2017 Abr 10]. Disponível em: http://www.who.int/pbd/ deafness/hearing_impairment_grades/en/.

Wasserstein RL, Lazar NA. The ASA's statement on P-values: context, process, and purpose. [Citado em 2016 Nov 11]. Am Stat. 2016; 70:129-33.

Altman DG, Bland JM. Statistics notes: absence of evidence is not evidence of absence. Br Med J. 1995; 311:485.

Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986; 292(6522):746-50.

StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC, 2017.

Baraky LR, Bento RF, Raposo NR, Tibiriçá SH, Ribeiro LC, Barone MM et al. Disabling hearing loss prevalence in Juiz de Fora, Brazil. Braz J Otorhinolaryngol. 2012; 78(4):52-8.

Lin BM, Curam SG, Wang M, Eavey R, Stankovic KM, Curhan GC. Hypertension, diuretic use, and risk of hearing loss. Am J Med. 2016; 129(4):416-22.

Rifkin SI, de Quesada AM, Pickering MJ, Shires DL Jr. Deafness associated with oral furosemide. Southern Medical Journal. 1978; 71:86-8.

Wang Z, Wang XHJ, Li Y, Hu H, Hu Y, Zhao X et al. Metabolic syndrome is associated with hearing loss among a middle-aged and older Chinese population: a cross-sectional study. Annals of Medicine. 2018; 50(7):587-95.

Aghazadeh-Attari J, Mansorian B, Mirza-Aghazadeh-Attari M, Ahmadzadeh J, Mohebbi I. Association between metabolic syndrome and sensorineural hearing loss: a cross-sectional study os 11,114 participants. Diabetes Metab Syndr Obes. 2017; 10:459-65.

Shena H, Zhanga B, Shina JH, Leia D, Dua Y, Gaob X et al. Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2008; 226(1-2):52-60.

Naples JG. Calcium-channel blockers as therapeutic agents for acquired sensorineural hearing loss. Med Hypotheses. 2017; 104:121-5.

Yu Y.F, Wu WY, Xiao GS, Ling HY, Pan C. Protection of the cochlear hair cells in adult C57BL/6J mice by T-type calcium channel blockers. Experimental and Therapeutic Medicine. 2016; 11:1039-44.

Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M et al. IL-10, IL-6, and TNFalpha: central factors in the altered cytokine network of uremia – the good, the bad, and the ugly. Kidney Int. 2005; 67:1216-33.

Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004; 65:1009-16.

Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2002; 16:1-4.

Cuna V, Battaglino G, Capelli I, Sala E, Donati G, Cianciolo G, La Manna G. Hypoacusia and chronic renal dysfunction: new etiopathogenetic prospective. Ther Apher Dial. 2015 Apr; 19(2):111-8.

Fujioka M, Okano H, Ogawa K. Inflammatory and immune responses in the cochlea: potential therapeutic targets for sensorineural hearing loss. Front Pharmacol. 2014. 23; 5:287.

Watson N, Ding B, Zhu X, Frisina RD. Chronic inflammation – inflammaging – in the ageing cochlea: a novel target for future presbycusis therapy. Ageing research reviews. 2017; 40:142-8.

Pathak S, Hatam LJ, Bonagura V, Vambutas A. Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease. J Clin Immunol. 2013; 33:1204-15.

World Health Organization. Global burden of hearing loss in the year 2000. [Citado em 2018 Out 20]. Disponível em: http://www.who.int/healthinfo/statistics/bod_hearingloss.pdf.

Downloads

Published

2020-06-08

How to Cite

1.
Assis Espindula Mota M, Otávio do Amaral Corrêa J, Erothildes Ferreira R, Rodrigues Mendes Moraes M, Parisi Marlière B, Antonio Basile Colugnati F. Hearing loss prevalence and associated factors in chronic kidney disease patients under conservative treatment. HU Rev [Internet]. 2020Jun.8 [cited 2024Jul.17];46:1-9. Available from: https://periodicos.ufjf.br/index.php/hurevista/article/view/28887

Issue

Vol. 46 (2020)

Section

Artigos Originais

License

Cessão de Primeira Publicação à HU Revista

Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.

 

 

Most read articles by the same author(s)